Welcome to our dedicated page for Abvc Biopharma SEC filings (Ticker: ABVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ABVC BioPharma, Inc. (NASDAQ: ABVC) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including annual and quarterly reports and current reports on Form 8-K. As a clinical-stage biopharmaceutical company focused on oncology/hematology, central nervous system disorders, and ophthalmology, ABVC uses these filings to describe its pipeline, licensing arrangements, financing activities, and other material events.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review management’s discussion of operating results, R&D spending, and the status of key programs such as CNS candidates for major depressive disorder and ADHD, oncology assets with US FDA-approved INDs, and the Vitargus® vitreous substitute device. These reports also outline intellectual property holdings, including patents on Polygala extract-based therapies and ophthalmology technologies, and discuss collaboration structures with partners like AiBtl BioPharma Inc., ForSeeCon Eye Corporation, and OncoX BioPharma Inc.
Current reports on Form 8-K capture specific events, such as licensing agreements, financing transactions, changes in the independent registered public accounting firm, and updates on Nasdaq listing compliance. They also reference press releases announcing financial results for particular quarters, providing timely insight into revenue from services and licensing payments, as well as changes in stockholders’ equity and debt arrangements.
On Stock Titan, ABVC filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items related to clinical progress, licensing economics, or capital structure. Real-time updates from the SEC’s EDGAR system ensure that new 10-K, 10-Q, and 8-K filings, along with any other relevant forms, appear promptly. Users can also monitor disclosures that may relate to executive or director equity awards and other equity incentive matters as described in ABVC’s filings.
ABVC BioPharma furnished an 8-K to announce its financial results for the third quarter ended September 30, 2025. The company reported these results via a press release attached as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104, the cover page interactive data file formatted in Inline XBRL. The notice states it is not an offer to sell or solicit purchases of securities.
ABVC BioPharma filed its Q3 2025 Form 10‑Q, reporting revenues of $795,950 for the quarter and $795,950 for the nine months. The company posted a net loss of $1,287,523 for Q3 and $4,564,546 for the nine months, with basic and diluted net loss per share of $0.05 and $0.23, respectively.
Total assets were $21,176,299 as of September 30, 2025, up from $7,539,907 at December 31, 2024, largely reflecting property and equipment, net, of $12,055,642, including land acquisitions in Taiwan. Cash and cash equivalents were $192,068, with restricted cash of $661,843. The company reported a working capital deficit of $2,434,951 and stated that these conditions give rise to substantial doubt about its ability to continue as a going concern.
Operating cash outflow was $1,567,264 for the nine months, offset by $3,488,478 provided by financing activities. The company recognized collaboration revenues from related‑party licensing, including $595,950 from an OncoX agreement and $200,000 from a FEYE amendment during the nine months. ABVC restated prior periods to correct share‑based payment accounting, interest recognition on a convertible note, and non‑controlling interest presentation. Shares outstanding were 24,301,089 as of October 30, 2025.
ABVC BioPharma (ABVC) approved a performance incentive plan for directors, officers, and select employees. The plan will only take effect after the company achieves a $1B market cap for 30 consecutive trading days on or before December 31, 2027, of which there is no guarantee.
If implemented, awards will equal 1% of the company’s common stock outstanding on the implementation date, sourced from the Amended and Restated 2016 Equity Incentive Plan. The plan is capped at $10 million in total awards, with a $1 million cap per recipient. Grants will be tied to defined milestones and require allocation by the Compensation Committee, endorsement by a majority of independent directors, and final approval by the full Board. The structure is intended to align leadership incentives with shareholder value creation.
ABVC BioPharma, Inc. filed an amended current report to update information about its former independent auditor. The company previously disclosed that WWC, P.C., its independent registered public accounting firm, agreed not to renew its engagement as of October 10, 2024.
In this amendment, ABVC explains that it had provided WWC with the earlier report and asked for a letter to the SEC stating whether WWC agreed with the company’s description of the circumstances. ABVC now reports that WWC has refused to provide that letter.
ABVC BioPharma, Inc. reported continued operating losses and a strained liquidity position while advancing multiple clinical programs and licensing arrangements. For the periods shown, the company recorded net losses of $2.33 million and $3.28 million (two comparable periods), with net loss attributable to ABVC of $2.26 million and $3.10 million in the comparable reporting periods. Basic and diluted net loss per share ranged from $(0.08) to $(0.36) depending on period and share count. Current liabilities totaled $6.53 million with a working capital deficit near $(3.76) million. Cash flows show investing uses of $(665,779) and financing proceeds of $2.54 million in the reporting period. Long-term investments and prepayments total several million, and the company discloses substantial related-party loans and short-term borrowings. Clinical pipeline progress includes completed Phase II for ABV-1504 (MDD), ongoing Phase II Part 2 for ABV-1505 (ADHD), planned Phase I for ABV-1601, and initiated Phase II for ABV-1701 Vitargus (medical device). License/milestone schedule includes $1M for IND, $1M for Phase II completion, $3M for Phase III initiation, and $4M for NDA submission.
ABVC BioPharma reported a loss and continuing financing reliance. The filing shows significant operating losses and negative working capital while the company advances multiple clinical and device programs.
For the period presented, net loss attributable to ABVC was $2,257,022 for the quarter and $3,099,097 for the six-month period, with basic and diluted net loss per share of $(0.13) and $(0.19) for the comparable periods. Current liabilities totaled $6,532,514 producing a working capital deficit of $(3,762,113). Long-term investments were $2,837,922 and property and equipment, net was reported at $8,215,366. Cash flow from financing activities provided $2,536,083 while investing used $(665,779). The company disclosed related-party loans and short-term borrowings, loaned funds to affiliates (BioFirst) and a warrant exercise arrangement with Lind to raise equity proceeds. The business continues multiple clinical programs (ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, ABV-1703) and milestone-based license payments tied to IND, Phase II, Phase III and NDA events.
ABVC BioPharma, Inc. reported continued operating losses and negative working capital while advancing multiple clinical programs and relying on financing and related-party support. For the six months ended June 30, 2025 the company recorded a net loss of $2.332 million versus a loss of $1.047 million in the prior period. Basic and diluted net loss per share for the quarter/period presented include $(0.13) and
ABVC BioPharma reported continued operating losses and negative working capital as of June 30, 2025. Revenue was nil while operating expenses rose to $2.29 million for the quarter, producing a net loss of $2.33 million for the quarter and $3.28 million for the six months ended June 30, 2025. Cash flows from operations were negative while financing activities provided $2.54 million, partially offsetting investing outflows of $0.67 million. Current liabilities totaled $6.53 million producing a working capital deficit of $3.76 million. The company holds long-term investments of $2.84 million and prepayments for investments and asset acquisitions totaling about $1.82 million. Clinical-stage assets include multiple drugs and a medical device in Phase I/II or Phase II, with milestones and licensing payments outlined for IND, Phase II, Phase III and NDA events.
ABVC BioPharma reports continued development-stage operations with multiple clinical programs and material losses. The company recorded net losses attributable to ABVC and subsidiaries of $2,257,022 and $942,336 in presented periods, and basic and diluted net loss per share figures shown of $(0.13), $(0.08), $(0.19), and $(0.36) for the periods reported. Current liabilities were stated at $6,532,514 and $6,557,461, and working capital deficits of $(3,762,113) and $(4,377,616) were disclosed. Cash flow provided by financing activities increased to $2,536,083 from $1,726,303, while cash flow used in investing activities was $(665,779).
The filing highlights active R&D: completed Phase II for ABV-1504 (MDD), Phase II Part 1 for ABV-1505 (ADHD) with Part 2 ongoing, planned Phase I for ABV-1601, and ongoing device study ABV-1701 (Vitargus®) in Phase II. Contractual milestone structure for licensing includes aggregate milestone payments of $10 million staged across IND, Phase II, Phase III and NDA events.
ABVC BioPharma, Inc. filed a current report to let investors know it has released its financial results for the second quarter ended June 30, 2025. The company states that these results are presented in a press release dated August 14, 2025, which is included as Exhibit 99.1. This information is being furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced. The report also clarifies that neither the document nor its exhibits constitute an offer to sell or a solicitation to buy any of ABVC’s securities.